(-0.04%) 5 476.50 points
(-0.07%) 38 791 points
(-0.01%) 19 919 points
(0.35%) $80.61
(1.22%) $2.82
(0.24%) $2 334.70
(-0.16%) $29.35
(-0.18%) $969.20
(0.01%) $0.932
(-0.15%) $10.64
(0.04%) $0.787
(-1.87%) $86.80
Live Chart Being Loaded With Signals
Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor that is in Phase IIa clinical trials for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties...
Stats | |
---|---|
Šios dienos apimtis | 1.94M |
Vidutinė apimtis | 876 957 |
Rinkos kapitalizacija | 582 482 |
EPS | $-0.180 ( Q3 | 2022-11-10 ) |
Last Dividend | $0.110 ( 2023-04-11 ) |
Next Dividend | $0 ( N/A ) |
P/E |
-0.142 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.00500 (58.82%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-02-15 | Hogan H Michael Iii | Buy | 0 | |
2022-12-30 | Weber David Allen | Sell | 91 636 | Common Stock |
2022-12-28 | Cayer Paul E | Sell | 40 054 | Common Stock |
2022-11-28 | Capps Vickie L | Sell | 42 242 | Common Stock |
2022-06-21 | Schroeder Theodore R | Buy | 27 500 | Stock Option (right to buy) |
INSIDER POWER |
---|
-68.64 |
Last 98 transactions |
Buy: 7 968 332 | Sell: 3 029 863 |
Tūris Koreliacija
Otonomy Inc Koreliacija
10 Labiausiai teigiamai susiję koreliacijos |
---|
10 Labiausiai neigiamai susiję koreliacijos |
---|
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Otonomy Inc Koreliacija - Valiuta/Žaliavos
Otonomy Inc Finansinės ataskaitos
Annual | 2021 |
Pajamos: | $125 000 |
Bruto pelnas: | $-245 000 (-196.00 %) |
EPS: | $-0.810 |
FY | 2021 |
Pajamos: | $125 000 |
Bruto pelnas: | $-245 000 (-196.00 %) |
EPS: | $-0.810 |
FY | 2020 |
Pajamos: | $273 000 |
Bruto pelnas: | $-915 000 (-335.16 %) |
EPS: | $-1.100 |
FY | 2019 |
Pajamos: | $600 000 |
Bruto pelnas: | $-312 000 (-52.00 %) |
EPS: | $-1.450 |
Financial Reports:
No articles found.
Otonomy Inc Dividends
(Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0.110 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | $0.110 | 2023-04-11 |
Last Dividend | $0.110 | 2023-04-11 |
Next Dividend | $0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 1 | -- |
Total Paid Out | $0.110 | -- |
Avg. Dividend % Per Year | 39.17% | -- |
Score | 4.01 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|---|---|
2023 | $0.110 | 117.50% |
2024 | $0 | 0.00% |
The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.
Ex Date | Amount | Declaration Date | Record Date | Payment Date |
---|---|---|---|---|
11 Apr 2023 | $0.110 | 30 Nov -0001 | 30 Nov -0001 | 30 Nov -0001 |
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
OXLC | Dividend Diamond | 2024-09-16 | Monthly | 14 | 15.03% | 9.60 |
DMLP | Dividend Diamond | 2024-04-26 | Quarterly | 22 | 10.71% | 9.35 |
OXSQ | Dividend Diamond | 2024-09-16 | Monthly | 21 | 12.73% | 9.02 |
ARLP | Dividend Royal | 2024-05-07 | Quarterly | 26 | 9.67% | 8.87 |
PNNT | Dividend Royal | 2024-06-14 | Monthly | 18 | 9.49% | 8.82 |
MFIC | Dividend Royal | 2024-06-11 | Quarterly | 21 | 10.89% | 8.79 |
SPOK | Dividend Royal | 2024-05-23 | Quarterly | 20 | 8.73% | 8.72 |
PSEC | Dividend Royal | 2024-06-25 | Monthly | 21 | 9.03% | 8.65 |
SBLK | Dividend Royal | 2024-06-06 | Quarterly | 17 | 13.10% | 8.63 |
GBDC | Dividend Royal | 2024-11-29 | Bi-Monthly | 15 | 8.53% | 8.62 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -402.60 | 1.500 | -10.00 | -10.00 | [0 - 0.5] |
returnOnAssetsTTM | -0.526 | 1.200 | -10.00 | -10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.0949 | 1.500 | -0.0565 | -0.0848 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 6.52 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 6.28 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 6.28 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.166 | -1.500 | 7.24 | -10.00 | [0 - 0.6] |
interestCoverageTTM | -31.04 | 1.000 | -10.00 | -10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | -0.669 | 2.00 | -0.223 | -0.446 | [0 - 30] |
freeCashFlowPerShareTTM | -0.673 | 2.00 | -0.337 | -0.673 | [0 - 20] |
debtEquityRatioTTM | -0.0285 | -1.500 | -0.114 | 0.171 | [0 - 2.5] |
grossProfitMarginTTM | -1.960 | 1.000 | -10.00 | -10.00 | [0.2 - 0.8] |
operatingProfitMarginTTM | -397.00 | 1.000 | -10.00 | -10.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -2.68 | 1.000 | -10.00 | -10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.00131 | 0.800 | -3.32 | -2.66 | [0.5 - 2] |
Total Score | -3.12 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -0.0107 | 1.000 | -0.102 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0949 | 2.50 | -0.0363 | -0.0848 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -0.673 | 2.00 | -0.224 | -0.673 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -0.669 | 2.00 | -0.223 | -0.446 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -0.000107 | 1.500 | -3.33 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -339.34 | 1.000 | -10.00 | 0 | [0.1 - 0.5] |
Total Score | -1.609 |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Otonomy Inc
Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor that is in Phase IIa clinical trials for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties. It also develops OTO-510, an otoprotectant for the prevention of cisplatin-induced hearing loss; OTO-825, a gene therapy for the treatment of congenital hearing loss; and OTO-6XX induces hair cell repair and regeneration for the treatment of severe hearing loss. The company has license agreements with University of California and DURECT Corporation; and strategic collaboration with Applied Genetic Technologies Corporation to develop and commercialize gene therapy for congenital hearing loss. Otonomy, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.